@rishabhcmi

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services
Industry Analysis Services
Business Consulting Services
Market Intelligence Services
Long term Engagement Model
Country Specific Analysis

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

https://www.coherentmarketinsights.com/market-insight/cns-specific-antisense-oligonucleotide-market-2477

Source:

CELL AND GENE THERAPY MARKET ANALYSIS

rishabhcmi — Fri, 22 Jan 2021 11:09:23 GMT

Cell therapy is the administration of living cells in patients for the treatment of a disease. The source of cell can be autologous or allogeneic, which can be derived from stem cells such as bone marrow. Stem cells therapy is used in bone marrow transplantation. Gene therapy is the introduction, removal, or change in the patient's genetic code for treatment of a disease. Moreover, it modifies the expression of an individual’s genes or repair abnormal genes. The therapy involves administration of nucleic acid (DNA/RNA) with carriers called as vectors.

Market Dynamics

Increasing prevalence of cancer diseases is a major factor driving the cell and gene therapy market growth. According to the World Cancer Research Funds and the American Institute for Cancer Research, in 2018, there were around 18 million cases of cancer, of which around 9.5 million were in men and around 8.5 million in women, globally. Moreover, introduction of innovative products and rich pipeline of cell and gene therapy is expected to boost the market growth. For instance, around 150 gene therapies are currently in the development stage. Gene replacement accounts for around two third of gene therapy pipeline. However, around 49% of gene therapies are under preclinical and discovery stages. During 2012-18, around 351 gene therapy deals were signed. For instance Gilead’s Kite Pharma received exclusive rights to Sangamo Therapeutics’ zinc finger nuclease gene editing technology, for $3.2bn.

Key features of the study:

This report provides in-depth analysis of the cell and gene therapy market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global cell and gene therapy market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Amgen, Biogen, BioMarin Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis, Pfizer, Regeneron Pharmaceuticals and Sanofi, Spark Therapeutics, Agilis Biotherapeutics, Angionetics AVROBIO, Freeline Therapeutics, Horama, MeiraGTx, Myonexus Therapeutics, Nightstar Therapeutics, Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., and MEDIPOST
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global cell and gene therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the cell and gene therapy market

Detailed Segmentation:

Global Cell and Gene Therapy Market, By Therapy Type:

Cell Therapy

Stem Cells
T Cells
Dendritic Cells
NK Cells
Tumor Cells

Gene Therapy

Global Cell and Gene Therapy Market, By Indication:

Cardiovascular Disease
Cancer
Genetic Disorder
Infectious Disease
Neurological Disorders
Others

Global Cell and Gene Therapy Market, By Scale of Operation:

In House
Outsourced

Global Cell and Gene Therapy Market, By Geography:

North America

By Therapy Type:

Cell Therapy

Stem Cells
T Cells
Dendritic Cells
NK Cells
Tumor Cells

Gene Therapy

By Indication:

Cardiovascular Disease
Cancer
Genetic Disorder
Infectious Disease
Neurological Disorders
Others

By Scale of Operation:

In House
Outsourced

By Country:

U.S.
Canada

Latin America

By Therapy Type:

Cell Therapy

Stem Cells
T Cells
Dendritic Cells
NK Cells
Tumor Cells

Gene Therapy

By Indication:

Cardiovascular Disease
Cancer
Genetic Disorder
Infectious Disease
Neurological Disorders
Others

By Scale of Operation:

In House
Outsourced

By Country:

Brazil
Mexico
Argentina
Rest of Latin America

Europe

By Therapy Type:

Cell Therapy

Stem Cells
T Cells
Dendritic Cells
NK Cells
Tumor Cells

Gene Therapy

By Indication:

Cardiovascular Disease
Cancer
Genetic Disorder
Infectious Disease
Neurological Disorders
Others

By Scale of Operation:

In House
Outsourced

By Country:

Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe

Asia Pacific

By Therapy Type:

Cell Therapy

Stem Cells
T Cells
Dendritic Cells
NK Cells
Tumor Cells

Gene Therapy

By Indication:

Cardiovascular Disease
Cancer
Genetic Disorder
Infectious Disease
Neurological Disorders
Others

By Scale of Operation:

In House
Outsourced

By Country:

China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific

Middle East

By Therapy Type:

Cell Therapy

Stem Cells
T Cells
Dendritic Cells
NK Cells
Tumor Cells

Gene Therapy

By Indication:

Cardiovascular Disease
Cancer
Genetic Disorder
Infectious Disease
Neurological Disorders
Others

By Scale of Operation:

In House
Outsourced

By Country:

GCC
Israel
Rest of Middle East

Africa

By Therapy Type:

Cell Therapy

Stem Cells
T Cells
Dendritic Cells
NK Cells
Tumor Cells

Gene Therapy

By Indication:

Cardiovascular Disease
Cancer
Genetic Disorder
Infectious Disease
Neurological Disorders
Others

By Scale of Operation:

In House
Outsourced

By Country:

South Africa
Central Africa
North Africa

Company Profiles

Amgen *

Company Overview
Product Portfolio
Financial Performance
Key Highlights
Market Strategies

Request the sample copy of here:

https://www.coherentmarketinsights.com/insight/request-sample/2475

Download the PDF Brochure here:

https://www.coherentmarketinsights.com/insight/request-pdf/2475

Buy now the market research report here:

https://www.coherentmarketinsights.com/insight/buy-now/2475

What we provide:

Customized Market Research Services
Industry Analysis Services
Business Consulting Services
Market Intelligence Services
Long term Engagement Model
Country Specific Analysis

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

https://www.coherentmarketinsights.com/market-insight/cell-and-gene-therapy-market-2475

Source:

BIORESORBABLE VASCULAR SCAFFOLD MARKET ANALYSIS

rishabhcmi — Fri, 22 Jan 2021 11:07:34 GMT

Bioresorbable vascular scaffold (BVS) is a nonmetallic mesh tube, which is used to treat blocked arteries. It is similar to a stent but gradually dissolves once the blocked artery starts functioning naturally again, enabling the artery to return to its natural state. The scaffold disappears in around 12-24 months and supports the vessel until it gain its full function. BVS is designed to help open up a blocked artery in the heart and restore blood flow to the heart muscle. It is used by patients who are suffering from different types of cardiovascular diseases. Some of the commonly used BVS for cardiac procedures include Poly-L-Lactide (PLLA) bioresorbable scaffold, metallic bioresorbable scaffold, and hybrid bioresorbable scaffold.

Market Dynamics

Increasing demand for bioresorbable vascular scaffold owing to high prevalence of coronary heart disease, ischemic heart disease, and other cardiovascular diseases is expected to drive market growth. According to American Heart Association Council, in 2015, cardiovascular disease was the leading cause of death in the world, accounting for over 17.9 million deaths per year globally, and this number is expected to increase to over 23.6 million by 2030. From the same source, cardiovascular diseases accounted for nearly 836,546 deaths in the U.S. in 2015, which is about 1 of every 3 deaths.

Moreover, key players are opting for different strategies such as new product launches, FDA approvals, partnerships, and collaborations to increase its foothold in the market. For instance, in July 2016, Abbott received the U.S. Food and Drug Administration approval for Absorb bioresorbable heart stent. This device is first-of-its-kind medical device with fully dissolving heart stents. This device will be available to treat people with coronary artery disease in the U.S.

However, preference for vascular graft devices for angioplasty and coronary artery diseases is one of the major factors restraining growth of the global bioresorbable vascular scaffold market. Furthermore, stringent regulatory scenario has also obstructed growth of the market.

Key features of the study:

This report provides in-depth analysis of the bioresorbable vascular scaffold market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles leading players in the global bioresorbable vascular scaffold market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Abbott Laboratories, Cook Medical, Boston Scientific Corporation, Stentys SA, MAQUET Holding B.V. & Co. KG (Getinge AB), W.L. Gore & Associates, Medtronic, C. R. Bard, Inc., B. Braun Melsungen AG, and Terumo Corporation among others
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global bioresorbable vascular scaffold market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for bioresorbable vascular scaffold market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

Global Bioresorbable Vascular Scaffold Market, By Product Type:

Synthetic
Biological

Global Bioresorbable Vascular Scaffold Market, By Material Type:

Metal based BVS
Polymer based BVS

Global Bioresorbable Vascular Scaffold Market, By Application

Coronary Artery Stents
Peripheral Artery Stents
Others

Global Bioresorbable Vascular Scaffold Market, By End User:

Hospitals
Ambulatory Surgical Centers
Cardiac Centers
Others

Global Bioresorbable Vascular Scaffold Market, By Geography:

North America

By Product Type:

Synthetic
Biological

By Material:

Metal based BVS
Polymer based BVS

By Application:

Coronary Artery Stents
Peripheral Artery Stents
Others

By End User:

Hospitals
Ambulatory Surgical Centers
Cardiac Centers
Others

By Country:

U.S.
Canada

Latin America

By Product Type:

Synthetic
Biological

By Material:

Metal based BVS
Polymer based BVS

By Application:

Coronary Artery Stents
Peripheral Artery Stents
Others

By End User:

Hospitals
Ambulatory Surgical Centers
Cardiac Centers
Others

By Country:

Brazil
Mexico
Argentina
Rest of Latin America

Europe

By Product Type:

Synthetic
Biological

By Material:

Metal based BVS
Polymer based BVS

By Application:

Coronary Artery Stents
Peripheral Artery Stents
Others

By End User:

Hospitals
Ambulatory Surgical Centers
Cardiac Centers
Others

By Country:

Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe

Asia Pacific

By Product Type:

Synthetic
Biological

By Material:

Metal based BVS
Polymer based BVS

By Application:

Coronary Artery Stents
Peripheral Artery Stents
Others

By End User:

Hospitals
Ambulatory Surgical Centers
Cardiac Centers
Others

By Country:

China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific

Middle East

By Product Type:

Synthetic
Biological

By Material:

Metal based BVS
Polymer based BVS

By Application:

Coronary Artery Stents
Peripheral Artery Stents
Others

By End User:

Hospitals
Ambulatory Surgical Centers
Cardiac Centers
Others

By Country:

GCC
Israel
Rest of Middle East

Africa

By Product Type:

Synthetic
Biological

By Material:

Metal based BVS
Polymer based BVS

By Application:

Coronary Artery Stents
Peripheral Artery Stents
Others

By End User:

Hospitals
Ambulatory Surgical Centers
Cardiac Centers
Others

By Country:

South Africa
Central Africa
North Africa

Company Profiles

Abbott Laboratories*

Company Overview
Product Portfolio
Financial Performance
Key Highlights
Market Strategies

Request the sample copy of here:

https://www.coherentmarketinsights.com/insight/request-sample/2471

Download the PDF Brochure here:

https://www.coherentmarketinsights.com/insight/request-pdf/2471

Buy now the market research report here:

https://www.coherentmarketinsights.com/insight/buy-now/2471

What we provide:

Customized Market Research Services
Industry Analysis Services
Business Consulting Services
Market Intelligence Services
Long term Engagement Model
Country Specific Analysis

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

https://www.coherentmarketinsights.com/market-insight/bioresorbable-vascular-scaffold-market-2471

Source:

TISSUE PLASMINOGEN ACTIVATOR MARKET ANALYSIS

rishabhcmi — Fri, 22 Jan 2021 11:05:39 GMT

Tissue plasminogen activator (tPA) is an enzyme associated with the disintegration of blood clots. It is a serine protease present in endothelial cells. With the help of serine protease, the conversion of plasminogen to plasmin is catalyzed. Serine protease is a major enzyme for clot disintegration.

tPA is also be produced by using recombinant technology techniques known as recombinant tissue plasminogen activator (rtPA). Specific rtPAs are tenecteplase, alteplase, and reteplase. These enzymes are used in clinical treatment of thrombotic stroke or embolic stroke. tPA is a drug that dissolves blood clots. It is a thrombolytic agent which can be administrated into the veins.

Global Tissue Plasminogen Activator Market: Drivers

Tissue plasminogen activator is the first and only drug approved by the FDA in 1996 for the treatment of acute ischemic stroke. Increasing incidences of stroke has boosted the tissue plasminogen activator market size. According to John Hopkins Medicines (JHM) in the U.S., around 795,000 people in the U.S. suffer from stroke per year, as reported in 2014. According to the World Health Organization (WHO), stroke is the second leading cause of death and the third leading cause of disability, worldwide, as reported in 2012. This is one of the major factors driving the tissue plasminogen activator market growth.

Increasing prevalence of stroke incidences in growing geriatric population is another major factor driving the market size. As per the Public Health England (PHE), around 38% of people suffering from strokes were aged 40 to 69 in 2018. Moreover, tissue plasminogen activator market revenue is witnessing further increase due to awareness about stroke and its symptoms. In 2015, the Centers of Disease Control and Prevention (CDC) stated that around 38% of people were able to recognize the major symptoms of stroke and were treated at the right time.

Global Tissue Plasminogen Activator Market: Restraints

The side effects such as nausea, vomiting, dizziness, and fever, of the drug is one of the factors hindering tissue plasminogen activator market growth. Major side effects include hypertension, intracranial hemorrhage, systemic hemorrhage, angioedema, and others. tPA also causes complications of left ventricle. In 2011, the National Center for Biotechnology Information recorded around 2% to 5% of patients with acute ischemic stroke receive rtPA in the U.S. In 2015, CDC reported around 140,000 deaths due to unavailability and adverse effects of tPA in the U.S.

Moreover, tissue plasminogen activator market growth can also be hampered by substitute product approvals by the Food and Drug Administration (FDA). For instance, after the approval of stent retriever by FDA, in 2012, the global tissue plasminogen activator market growth was affected, since tPA is not effective for major blood clots in comparison to the stent retriever thrombectomy.

Global Tissue Plasminogen Activator Market: Regional Analysis

North America is the leader in the global tissue plasminogen activator market, owing to rising awareness about stroke and huge spending on treatment of stroke. For instance, in 2017, the American Heart Association (AHA) recorded stroke costs as US$ 34 billion in the U.S. every year, which includes medicines for the treatment of stroke and cost of health care services.

Asia pacific is the fastest growing region in the tissue plasminogen activator market, owing to increasing demand drug coupled with rising stroke incidences in the region. According to WHO, Indonesia, Philippines, China, and India have highest rates of stroke, which is 186.3, 134.7, 128, and 71.5, respectively, as recorded in 2017.

Global Tissue Plasminogen Activator Market: Competitive Landscape

Key players operating in the global tissue plasminogen activator market include Bayer AG, Abcam, Calbiochem, Merck & Company, Roche, Sekisui Diagnostics, Genentech, Sigma-Aldrich, Taj Pharmaceuticals, and Cadila Healthcare Ltd.

Global Tissue Plasminogen Activator Market: Taxonomy

The global tissue plasminogen activator market is segmented on the basis of dosage, route of administration, application, and region.

By Dosage

2mg
50mg
100mg

By Route of administration

Intravenous
Regional intra-arterial

By Application

Blood clots
Pulmonary embolism
Myocardial infarction
Stroke

By Region

North America
Latin America
Europe
Asia Pacific
Middle East
Africa

Request the sample copy of here:

https://www.coherentmarketinsights.com/insight/request-sample/2469

Download the PDF Brochure here:

https://www.coherentmarketinsights.com/insight/request-pdf/2469

Buy now the market research report here:

https://www.coherentmarketinsights.com/insight/buy-now/2469

What we provide:

Customized Market Research Services
Industry Analysis Services
Business Consulting Services
Market Intelligence Services
Long term Engagement Model
Country Specific Analysis

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

https://www.coherentmarketinsights.com/ongoing-insight/tissue-plasminogen-activator-market-2469

Source:

SCHIZOPHRENIA THERAPEUTIC MARKET ANALYSIS

rishabhcmi — Fri, 22 Jan 2021 11:03:20 GMT

Schizophrenia is a mental disorder where the patient suffers from inability to understand the reality, decreased ability of thinking, abnormal behavior, and strange speech. Furthermore, the patient suffers from reduced emotional expression, anxiety, depression or less social engagement. According to the Brain & Behavior Research Foundation, schizophrenia generally occurs between the ages of 16-30. Although the main cause of schizophrenia is unknown, possible reasons are genetic, environmental factors or poor nutrition during pregnancy.

Treatment for schizophrenia include, psychological therapies, behavioral therapies, and antipsychotic drugs. Electroconvulsive therapies also aid in the treatment of schizophrenia. In severe cases, hospitalization is necessary for a short period of time.

Global Schizophrenia Therapeutic Market Drivers

The global schizophrenia therapeutic market size is expected to expand, owing to increasing prevalence of schizophrenia. In 2018, World Health Organization (WHO) reported that over 23 million patients were affected by schizophrenia worldwide. Furthermore, increasing approvals of therapies with second generation antipsychotic drugs such as Risperidone, Paliperidone, Olanzapine, and Lurasidone, which have less side effects is also expected to drive the global schizophrenia therapeutic market revenue. For instance, in 2015, the U.S. Food and Drugs Administration (FDA) approved Vraylar (Cariprazine), which was tested on 1,750 patients. The drug showed effective reduction of symptoms in schizophrenia in less time.

Global Schizophrenia Therapeutic Restraints

The common negligence and stigma regarding schizophrenia is one of the major restraining factors for hampering the schizophrenia therapeutic market growth. For instance, in 2018, the Schizophrenia and Related Disorders Alliance of America (SARDAA) reported that around 50% of people diagnosed with schizophrenia do not receive treatment, owing to negligence for mental health.

Moreover, the side effects caused by antipsychotics such as weight gain, dizziness, restlessness, nausea, blurred vision, low blood pressure, seizures, and constipation can also be negative growth rendering factor for the global schizophrenia therapeutic market revenue. For instance, according to National Centre for Biotechnology Information (NCBI) 2017 findings, obesity is affecting 15%-72% patients, 12% of patients are suffering from diabetes, and the prevalence of constipation is 39% in schizophrenic patients. Consumption of antipsychotics may also lead to sudden cardiac death and ventricular arrhythmia.

Global Schizophrenia Therapeutic Market Regional Analysis

North America holds dominant position in the schizophrenia therapeutic market, owing to increasing incidences of schizophrenia and high investment in schizophrenia therapy in the region. According to SARDAA, around 3.2 to 3.5 million people in the U.S. were suffering from schizophrenia in 2013. According to the same source, around US$ 32 to US$ 65 billion are annually spent on treatment and other economic costs of schizophrenia in the U.S.

Asia Pacific is fastest growing region in schizophrenia therapeutic market due to high prevalence of schizophrenia in economies such as China and India. According to NCBI 2014 data, prevalence of schizophrenia in China was 4.62 per 1000 people. Schizophrenia therapeutic market size is also expected to boost due to launch of new medicines in China. For instance, Janssen Pharmaceutical Companies of Johnson & Johnson launched INVEGA TRINZA in 2018 for the treatment of schizophrenia in China. INVEGA TRINZA is a three-month long-acting atypical antipsychotic drug for insomnia.

Global Schizophrenia Therapeutic Market Key Players

Key players operating in the global schizophrenia therapeutic market include, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Johnson & Johnson, Pfizer, Sandoz Canada Inc., Intas Pharmaceuticals, Novartis AG, Otsuka Pharmaceuticals, Alkermes, Allergan (Forest Labs), and Sumitomo Dainippon Pharma.

Global Schizophrenia Therapeutic Market Taxonomy:

The global schizophrenia therapeutic market is segmented on the basis of drug type, distribution channel, and region.

By Drug Type:

First Generation Antipsychotic Drugs
Second Generation Antipsychotic Drugs

By Distribution Channel

Hospital pharmacy
Retail pharmacy
Online pharmacy

By Region:

North America
Latin America
Europe
Asia Pacific
Middle East
Africa

Request the sample copy of here:

https://www.coherentmarketinsights.com/insight/request-sample/2468

Download the PDF Brochure here:

https://www.coherentmarketinsights.com/insight/request-pdf/2468

Buy now the market research report here:

https://www.coherentmarketinsights.com/insight/buy-now/2468

What we provide:

Customized Market Research Services
Industry Analysis Services
Business Consulting Services
Market Intelligence Services
Long term Engagement Model
Country Specific Analysis

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

https://www.coherentmarketinsights.com/ongoing-insight/schizophrenia-therapeutic-market-2468

Source:

MAGNETOENCEPHALOGRAPHY MARKET ANALYSIS

rishabhcmi — Fri, 22 Jan 2021 11:01:44 GMT

Magnetoencephalography (MEG) is one of the medical neuroimaging techniques which tracks the brain activity by measuring the magnetic field produced by neurons in the brain. It is a non-invasive technique which is safe, radiation-free, and also can be used for the pediatric population MEG device consists of numerous and highly sensitive magnetometers called Superconducting Quantum Interface Device (SQUID). MEG tests can be used for diagnosing diseases such as Alzheimer’s disease, epilepsy, and brain tumors.

It also offers real-time resolution as it is capable of providing results in milliseconds and identifies the primary location of brain activation. A MEG device captures brain activity by detecting and amplifying magnetic signals produced by the brain, and it does not emit radiation or create magnetic fields in the surrounding

Market Dynamics

Increasing awareness and diagnosis of mental illness or brain injury is expected to boost growth of the global magnetoencephalography market over the forecast period. According to the National Institute of Mental Health (NIMH), in 2016, around 44.7 million people of 18 years of age and above in the U.S. suffered from mental health disorders, and around 19.2 million people were diagnosed and received treatment.

However, factors such as low availability of MEG devices is expected to hinder growth of the magnetoencephalography devices market over the forecast period. For instance, in 2015, the European MEG Society (EMEGS) surveyed 44 MEG centers in 10 different countries, of which only 12 centers were using MEG for clinical purpose. Furthermore, high cost and maintenance cost of MEG device is a barrier for adoption of MEG, as single MEG device costs around US$ 2 million to US$ 3 million.

Key features of the study:

This report provides in-depth analysis of the magnetoencephalography devices market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period, 2019 – 2026, considering 2018 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players.
It profiles key players in the magnetoencephalography devices market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, strategies and key developments.

Key players covered as a part of this study include Compumedics Limited, Croton Healthcare, Ricoh Company, Ltd., and CTF MEG International Services LP

Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The magnetoencephalography devices market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for magnetoencephalography devices market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

Global Magnetoencephalography Devices Market, by Application:

Clinical Applications

Dementia
Autism
Schizophrenia
Multiple Sclerosis
Stroke
Epilepsy
Traumatic Brain Injury
Brain Tumor

Research Applications

Global Magnetoencephalography Devices Market, by End User:

Hospitals
Imaging Centers
Academic & Research Institutes

Global Magnetoencephalography Devices Market, by Region:

North America

By Country:

U.S.
Canada

By Application:

Clinical Applications

Dementia
Autism
Schizophrenia
Multiple Sclerosis
Stroke
Epilepsy
Traumatic Brain Injury
Brain Tumor

Research Applications

By End User:

Hospitals
Imaging Centers
Academic & Research Institutes

Europe

By Country:

U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe

By Application:

Clinical Applications

Dementia
Autism
Schizophrenia
Multiple Sclerosis
Stroke
Epilepsy
Traumatic Brain Injury
Brain Tumor

Research Applications

By End User:

Hospitals
Imaging Centers
Academic & Research Institutes

Asia Pacific

By Country:

Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific

By Application:

Clinical Applications

Dementia
Autism
Schizophrenia
Multiple Sclerosis
Stroke
Epilepsy
Traumatic Brain Injury
Brain Tumor

Research Applications

By End User:

Hospitals
Imaging Centers
Academic & Research Institutes

Latin America

By Country:

Brazil
Mexico
Argentina
Rest of Latin America

By Application:

Clinical Applications

Dementia
Autism
Schizophrenia
Multiple Sclerosis
Stroke
Epilepsy
Traumatic Brain Injury
Brain Tumor

Research Applications

By End User:

Hospitals
Imaging Centers
Academic & Research Institutes

Middle East

By Country:

GCC
Israel
Rest of Middle East

By Application:

Clinical Applications

Dementia
Autism
Schizophrenia
Multiple Sclerosis
Stroke
Epilepsy
Traumatic Brain Injury
Brain Tumor

Research Applications

By End User:

Hospitals
Imaging Centers
Academic & Research Institutes

Africa

By Country/Region:

South Africa
Central Africa
North Africa

By Application:

Clinical Applications

Dementia
Autism
Schizophrenia
Multiple Sclerosis
Stroke
Epilepsy
Traumatic Brain Injury
Brain Tumor

Research Applications

By End User:

Hospitals
Imaging Centers
Academic & Research Institutes

Company Profiles

Merck & Co. Inc.*

Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies

Request the sample copy of here:

https://www.coherentmarketinsights.com/insight/request-sample/2467

Download the PDF Brochure here:

https://www.coherentmarketinsights.com/insight/request-pdf/2467

Buy now the market research report here:

https://www.coherentmarketinsights.com/insight/buy-now/2467

What we provide:

Customized Market Research Services
Industry Analysis Services
Business Consulting Services
Market Intelligence Services
Long term Engagement Model
Country Specific Analysis

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

https://www.coherentmarketinsights.com/market-insight/magnetoencephalography-market-2467

Source:

PULMONARY FIBROSIS TREATMENT MARKET ANALYSIS

rishabhcmi — Fri, 22 Jan 2021 10:59:33 GMT

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease distinguished by progressive and irreversible reduction in lung function characterized by thickening and damaging of the walls of the air sacs (called alveoli). Common symptoms include, dry cough, gradual onset of shortness of breath, nail clubbing, and fatigue. Other symptoms are weight loss and muscle and joint pain. Further complications include, hypertension, heart failure, pulmonary embolism or pneumonia.

Major factors causing damage to the lungs include, acid reflux from stomach, certain viruses such as Epstein Barr virus and herpes virus or environmental factors such as breathing in dust such as silica dust, asbestos fibers, hard metal dust, and coal dust. Treatments for idiopathic pulmonary fibrosis (IPF) include, oxygen therapy, pulmonary rehabilitation, symptom management, and lung transplant. Prescribed antifibrotic drugs include, Pirfenidone and Nintedanib.

Global Idiopathic Pulmonary Fibrosis Treatment Market: Drivers

The idiopathic pulmonary fibrosis treatment market size is expected to witness significant growth, owing to increasing geriatric population. According to National Institute of Health’s (NIH), 2015 report, the symptoms of IPF starts occurring at the age of 50 to 70 in the U.S. Moreover, increasing prevalence of idiopathic pulmonary fibrosis is also expected to boost the market growth. According to NIH 2015 estimates, the prevalence of idiopathic pulmonary fibrosis is 13-20 per 100,000 people worldwide.

Smoking is believed to be another cause of idiopathic pulmonary fibrosis. According to the Centers for Disease Control and Prevention (CDC), around 1 billion smokers were recorded worldwide in 2017. The global idiopathic pulmonary fibrosis treatment market revenue is expected to witness significant growth, owing to availability of antifibrotic drugs IPF such as Pirfenidone (Esbriet) and Nintedanib (Ofev). According to annual reports of F. Hoffmann-La Roche AG, worldwide sales of Esbriet in 2016 was US$ 753 million.

Global Idiopathic Pulmonary Fibrosis Treatment Market: Restraints

Lack of awareness and availability of proper treatment is expected to hinder the idiopathic pulmonary fibrosis market growth. According to National Center for Biotechnology Information (NCBI) 2017 report, 54% patients do not receive any antifibrotic treatment in Europe.

Moreover, misdiagnosis of IPF is also expected to hinder the idiopathic pulmonary fibrosis treatment market size. For instance, according to Multidisciplinary Respiratory Medicines (MRM), in 2012, around 50% of IPF cases were misdiagnosed for other lung diseases in the U.S. High cost associated with the treatment of idiopathic pulmonary fibrosis is also expected to hinder the market growth. For instance, as per the data published in American Journal of Managed Care (AJMC) in 2014, idiopathic pulmonary fibrosis treatment requires US$ 100,000 annually, in the U.S.

Global Idiopathic Pulmonary Fibrosis Treatment Market: Regional Analysis

North America held dominant position in the idiopathic pulmonary fibrosis market in 2017, owing to rising incidence of idiopathic pulmonary fibrosis. According to NIH, 2015, around 100,000 people suffer from IPF and 30,000 to 40,000 new patients are diagnosed with the disease, annually in the U.S. Moreover, increasing approval of new drugs is also expected to boost the idiopathic pulmonary fibrosis treatment market growth in the region. For instance, in 2015, Prometic Life Sciences Inc. received the first orphan drug approval for PBI- 4050 from the U.S. Food and Drug Administration (FDA). Similarly, in 2017, Plasminogen (Ryplazim) was approved as an orphan drug by the U.S. FDA.

In 2017, Europe accounted for the second largest region in the idiopathic pulmonary fibrosis treatment market, owing to increasing prevalence of IPF in the region. For instance, in 2015, The European Pulmonary Fibrosis Patient Charter recorded around 80,000 to 111,000 people that were suffering from IPF and 30,000 to 35,000 patients are diagnosed with the disease, annually in Europe. Asia Pacific idiopathic pulmonary fibrosis market is expected to witness significant growth over the forecast period, owing to increasing number of people addicted to smoking in the region. For instance, in 2017, According to World Bank Data, over 30% of smokers worldwide were recorded in Asia Pacific.

Global Idiopathic Pulmonary Fibrosis Treatment Market: Competitive Landscape

Major players operating in the global idiopathic pulmonary fibrosis treatment market include, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb Company, Cipla, F. Hoffmann-La Roche, FibroGen, Inc., Galapagos NV, MediciNova, Inc., Merck & Co., Inc., Promedior, Inc., and Prometic Life Sciences Inc.

Global Idiopathic Pulmonary Fibrosis Treatment Market: Taxonomy

The global idiopathic pulmonary fibrosis market is segmented on the basis of drug type, formulation, distribution channel, and region.

By Drug Type

Pirfenidone

Nintedanib

By Formulation

Tablets
Soft Capsules

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Region

North America
Latin America
Europe
Asia Pacific
Middle East
Africa

Request the sample copy of here:

https://www.coherentmarketinsights.com/insight/request-sample/2466

Download the PDF Brochure here:

https://www.coherentmarketinsights.com/insight/request-pdf/2466

Buy now the market research report here:

https://www.coherentmarketinsights.com/insight/buy-now/2466

What we provide:

Customized Market Research Services
Industry Analysis Services
Business Consulting Services
Market Intelligence Services
Long term Engagement Model
Country Specific Analysis

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

https://www.coherentmarketinsights.com/ongoing-insight/idiopathic-pulmonary-fibrosis-treatment-market-2466

Source:

DRUG ELUTING BALLOON MARKET ANALYSIS

rishabhcmi — Fri, 22 Jan 2021 10:57:21 GMT

Drug eluting balloons are angioplasty balloons that are coated with an anti-proliferative drug, which is eluted in vessel walls during the inflation of balloon, usually at nominal pressure with a specific minimal inflation time. The active substance coated on the drug eluting balloon should be lipophilic in nature to have a high absorption rate through the vessel wall. Mostly paclitaxel is used as active ingredient due to its high pharmacokinetic transfer rate into the vessel wall and it is actively used in drug eluting balloons in the U.S. market and has been already approved for use in Europe.

Market Dynamics

Increasing prevalence of coronary artery diseases is a major factor driving drug eluting balloon market growth. According to American College of Cardiology, June 2017, around 17.92 million cardiovascular deaths were registered in 2015 worldwide. Moreover, key players in the market are focused on adopting acquisition strategies in order to gain access to innovative products and expand their product offerings in the potential markets. For instance, in April 2010, Medtronic acquired Invatec and affiliated companies. Invatec launched 4 new drug eluting balloons in Europe in 2009 including In.Pact Amphirion, In.Pact Admiral, In.Pact Pacific, and In.Pact Falcon. Medtronic is focused on enhancing its international presence by expanding treatment option for patients with cardiovascular disease.

Key features of the study:

This report provides in-depth analysis of the drug eluting balloon market and provides market size (US$ million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
It profiles key players in the global drug eluting balloon market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include, Medtronic, Becton, Dickinson and Company (BD), Boston Scientific Corporation, Cook Medical, B. Braun Melsungen AG, Koninklijke Philips N.V., Opto Circuits (India) Limited, Terumo Corporation, Surmodics, Inc., and Biotronik.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global drug eluting balloon market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the drug eluting balloon market

Detailed Segmentation:

Global Drug Eluting Balloon Market, By Product Type:

Coronary Drug Eluting Balloon
Peripheral Drug Eluting Balloon
Others

Global Drug Eluting Balloon Market, By End User:

Hospitals
CATH Laboratories
Ambulatory Surgical Centers
Others

Global Drug Eluting Balloon Market, By Geography:

North America

By Product Type:

Coronary Drug Eluting Balloon
Peripheral Drug Eluting Balloon
Others

By End User:

Hospitals
CATH Laboratories
Ambulatory Surgery Centers
Others

By Country:

U.S.
Canada

Latin America

By Product Type:

Coronary Drug Eluting Balloon
Peripheral Drug Eluting Balloon
Others

By End User:

Hospitals
CATH Laboratories
Ambulatory Surgery Centers
Others

By Country:

Brazil
Mexico
Argentina
Rest of Latin America

Europe

By Product Type:

Coronary Drug Eluting Balloon
Peripheral Drug Eluting Balloon
Others

By End User:

Hospitals
CATH Laboratories
Ambulatory Surgery Centers
Others

By Country:

Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe

Asia Pacific

By Product Type:

Coronary Drug Eluting Balloon
Peripheral Drug Eluting Balloon
Others

By End User:

Hospitals
CATH Laboratories
Ambulatory Surgery Centers
Others

By Country:

China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific

Middle East

By Product Type:

Coronary Drug Eluting Balloon
Peripheral Drug Eluting Balloon
Others

By End User:

Hospitals
CATH Laboratories
Ambulatory Surgery Centers
Others

By Country:

GCC
Israel
Rest of Middle East

Africa

By Product Type:

Coronary Drug Eluting Balloon
Peripheral Drug Eluting Balloon
Others

By End User:

Hospitals
CATH Laboratories
Ambulatory Surgery Centers
Others

By Country:

South Africa
Central Africa
North Africa

Company Profiles

Medtronic *

Company Overview
Product Portfolio
Financial Performance
Key Highlights
Market Strategies

Becton, Dickinson and Company
Boston Scientific Corporation
Cook Medical
B. Braun Melsungen AG
Koninklijke Philips N.V.
Opto Circuits (India) Limited
Terumo Corporation
Surmodics, Inc.
Biotronik

Request the sample copy of here:

https://www.coherentmarketinsights.com/insight/request-sample/2459

Download the PDF Brochure here:

https://www.coherentmarketinsights.com/insight/request-pdf/2459

Buy now the market research report here:

https://www.coherentmarketinsights.com/insight/buy-now/2459

What we provide:

Customized Market Research Services
Industry Analysis Services
Business Consulting Services
Market Intelligence Services
Long term Engagement Model
Country Specific Analysis

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

https://www.coherentmarketinsights.com/market-insight/drug-eluting-balloon-market-2459

Source:

PEMETREXED MARKET ANALYSIS

rishabhcmi — Fri, 22 Jan 2021 10:55:22 GMT

Pemetrexed is a chemotherapy drug indicated for the treatment of pleural mesothelioma and non-small cell lung cancer. Pemetrexed is a patented drug of Eli Lilly and Company and sold under brand name Alimta. In 2004, Alimta (Pemetrexed injection) was approved by FDA in combination with cisplatin as an initial treatment for patients with malignant pleural mesothelioma. In 2008, ALIMTA, in combination with cisplatin, was approved as an initial chemotherapy treatment for locally advanced or metastatic NSCLC for patients with nonsquamous histology, and in 2009, ALIMTA was approved as a maintenance therapy for locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC).

Market Dynamics

Launch of generic version of pemetrexed in key region is expected to increase affordability of pemetrexed, which in turn is expected to support global pemetrexed market growth over the forecast period.

For instance, in July 2018, STADAPHARM GmbH, the subsidiary of STADA Arzneimittel AG launched Pemetrexed STADA generic version of Alimta in Europe.

High prevalence of non-small cell lung cancer and pleural mesothelioma is expected to rise the demand for Pemetrexed for its treatment and support global pemetrexed market growth over the forecast period.

For instance, according to the data published by American Society of Clinical Oncology, in January 2018, in the U.S. around 234,030 adults (121,680 men and 112,350 women) were diagnosed with lung cancer among which non-small cell lung cancer is the most common type of lung cancer, accounting for 80% to 85% of all lung cancer diagnose.

Furthermore, key players in the market are dedicated to expand the indication of its Pemetrexed drugs in order to increase its sale and generate high revenues. For instance, in June 2018, Eli Lilly and Company received the U.S. Food and Drug Administration (FDA) approval for a new indication for ALIMTA (pemetrexed for injection) in combination with carboplatin and KEYTRUDA (pembrolizumab) for the initial treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression status.

Key features of the study:

This report provides in-depth analysis of Pemetrexed market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by leading players
It profiles leading players in the global Pemetrexed market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
Key companies covered as a part of this study include Eli Lilly and Company, Stada Arzneimittel AG, Eagle Pharmaceuticals, Inc., and Others
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global Pemetrexed market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Pemetrexed market

Detailed Segmentation:

Global Pemetrexed Market, By Strength :

100 mg
500 mg

Global Pemetrexed Market, By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Pemetrexed Market, By Region:

North America

By Strength :

100 mg
500 mg

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Country:

U.S.
Canada

Europe

By Strength :

100 mg
500 mg

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Country:

U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe

Asia Pacific

By Strength :

100 mg
500 mg

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Country:

China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific

Latin America

By Strength :

100 mg
500 mg

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Country:

Brazil
Mexico
Argentina
Rest of Latin America

Middle East

By Strength :

100 mg
500 mg

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Country:

GCC
Israel
Rest of Middle East

Africa

By Strength :

100 mg
500 mg

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Country:

Central Africa
South Africa
North Africa

Company Profiles

Eli Lilly and Company *

Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments

Request the sample copy of here:

https://www.coherentmarketinsights.com/insight/request-sample/2458

Download the PDF Brochure here:

https://www.coherentmarketinsights.com/insight/request-pdf/2458

Buy now the market research report here:

https://www.coherentmarketinsights.com/insight/buy-now/2458

What we provide:

Customized Market Research Services
Industry Analysis Services
Business Consulting Services
Market Intelligence Services
Long term Engagement Model
Country Specific Analysis

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

https://www.coherentmarketinsights.com/market-insight/pemetrexed-market-2458

Source:

ASIA PACIFIC HIV DIAGNOSTICS MARKET ANALYSIS

rishabhcmi — Fri, 22 Jan 2021 10:53:17 GMT

Although the most efficient test results are obtained by Enzyme-Linked Immunosorbent Assay (ELISA) test initially and later by Western blot method, HIV diagnosis can be performed by blood test, saliva test, and viral load test. The ELISA test is an enzyme-linked immunosorbent assay and uses antibodies to identify the substance. The Western blot technique is used to detect anti –HIV antibodies in the human serum sample. According to WHO, the HIV diagnosis includes free –standing sites, testing services in health care facilities, some community-based approaches and HIV self-testing (HIVST).

Market Dynamics

Increasing engagement programs by various government bodies to reduce disease burden of HIV epidemics and growing need for safe blood transfusion and donations in Asia Pacific is expected to drive the HIV diagnostic market size during the forecast period. For instance, India plans to make Pre-exposure prophylaxis (PrEP) available to men who have sex with men (MSM) and transgender women. The Indian Council of Medical Research (ICMR) indicated in November 2018 that it is planning to study the effectiveness of PrEP in high-risk groups.

However, stigma and social ostracism associated with HIV infections and diseases is expected to hinder the timely HIV diagnostics and treatment. Moreover, the fear of being tested positive, discrimination, rejection, and stigma restricts several people from conducting screening voluntarily. The fear of discord in marital relationships is yet another challenge where testing HIV positive is often seen as a case of infidelity. Therefore, these factors are expected to hamper the market growth.

Key features of the study:

This report provides in-depth analysis of the Asia Pacific HIV diagnostics market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Asia Pacific HIV diagnostics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include, Abbott Laboratories, Merck KGaA, F. Hoffmann-La Roche AG, Atomo diagnostics, Siemens Healthineers, Inc., bioLytical Laboratories Inc., MedMira Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., and Danaher Corporation
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The Asia Pacific HIV diagnostics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for Asia Pacific HIV Diagnostics market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

Asia Pacific HIV Diagnostics Market, By Product Type:

Instruments
Reagents & Kits

Asia Pacific HIV Diagnostics Market, By Test Type:

Screening

Third Generation
Fourth Generation

Differentiation & Confirmation Test
Monitoring Test

CD4 Tests
Viral Load Tests

Asia Pacific HIV Diagnostics Market, By End User:

Hospitals and Clinics
Diagnostic Laboratories
Home Care Settings
Others

Asia Pacific HIV Diagnostics Market, By Country:

Japan

By Product Type:

Instruments
Reagents & Kits

By Test Type:

Screening

Third Generation
Fourth Generation

Differentiation & Confirmation Test
Monitoring Test

CD4 Tests
Viral Load Tests

By End User:

Hospitals and Clinics
Diagnostic Laboratories
Home Care Settings
Others

China

By Product Type:

Instruments
Reagents & Kits

By Test Type:

Screening

Third Generation
Fourth Generation

Differentiation & Confirmation Test
Monitoring Test

CD4 Tests
Viral Load Tests

By End User:

Hospitals and Clinics
Diagnostic Laboratories
Home Care Settings
Others

South Korea

By Product Type:

Instruments
Reagents & Kits

By Test Type:

Screening

Third Generation
Fourth Generation

Differentiation & Confirmation Test
Monitoring Test

CD4 Tests
Viral Load Tests

By End User:

Hospitals and Clinics
Diagnostic Laboratories
Home Care Settings
Others

ASEAN

By Product Type:

Instruments
Reagents & Kits

By Test Type:

Screening

Third Generation
Fourth Generation

Differentiation & Confirmation Test
Monitoring Test

CD4 Tests
Viral Load Tests

By End User:

Hospitals and Clinics
Diagnostic Laboratories
Home Care Settings
Others

Australia

By Product Type:

Instruments
Reagents & Kits

By Test Type:

Screening

Third Generation
Fourth Generation

Differentiation & Confirmation Test
Monitoring Test

CD4 Tests
Viral Load Tests

By End User:

Hospitals and Clinics
Diagnostic Laboratories
Home Care Settings
Others

India

By Product Type:

Instruments
Reagents & Kits

By Test Type:

Screening

Third Generation
Fourth Generation

Differentiation & Confirmation Test
Monitoring Test

CD4 Tests
Viral Load Tests

By End User:

Hospitals and Clinics
Diagnostic Laboratories
Home Care Settings
Others

Rest of APAC

By Product Type:

Instruments
Reagents & Kits

By Test Type:

Screening

Third Generation
Fourth Generation

Differentiation & Confirmation Test
Monitoring Test

CD4 Tests
Viral Load Tests

By End User:

Hospitals and Clinics
Diagnostic Laboratories
Home Care Settings
Others

Company Profiles

Abbott Laboratories*

Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies

Merck KGaA
Hoffmann-La Roche AG
Atomo Diagnostics
Siemens Healthineers, Inc.
bioLytical Laboratories Inc.
MedMira Inc.
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
Danaher Corporation

Request the sample copy of here:

https://www.coherentmarketinsights.com/insight/request-sample/2457

Download the PDF Brochure here:

https://www.coherentmarketinsights.com/insight/request-pdf/2457

Buy now the market research report here:

https://www.coherentmarketinsights.com/insight/buy-now/2457

What we provide:

Customized Market Research Services
Industry Analysis Services
Business Consulting Services
Market Intelligence Services
Long term Engagement Model
Country Specific Analysis

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702